533 related articles for article (PubMed ID: 12657354)
1. The role of dihydrotestosterone in benign prostatic hyperplasia.
Carson C; Rittmaster R
Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
5. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
Dadras SS; Cai X; Abasolo I; Wang Z
Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
8. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
9. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
10. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
11. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.
Isaacs JT
J Steroid Biochem; 1983 Jun; 18(6):749-57. PubMed ID: 6191128
[TBL] [Abstract][Full Text] [Related]
12. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.
Bhasin S; Travison TG; Storer TW; Lakshman K; Kaushik M; Mazer NA; Ngyuen AH; Davda MN; Jara H; Aakil A; Anderson S; Knapp PE; Hanka S; Mohammed N; Daou P; Miciek R; Ulloor J; Zhang A; Brooks B; Orwoll K; Hede-Brierley L; Eder R; Elmi A; Bhasin G; Collins L; Singh R; Basaria S
JAMA; 2012 Mar; 307(9):931-9. PubMed ID: 22396515
[TBL] [Abstract][Full Text] [Related]
13. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
14. Prolactin influences upon androgen action in male accessory sex organs.
Thomas JA; Keenan EJ
Adv Sex Horm Res; 1976; 2():425-70. PubMed ID: 189591
[TBL] [Abstract][Full Text] [Related]
15. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormones and the pathogenesis of benign prostatic hyperplasia.
Griffiths K; Eaton CL; Harper ME; Peeling B; Davies P
Eur Urol; 1991; 20 Suppl 1():68-77. PubMed ID: 1722166
[TBL] [Abstract][Full Text] [Related]
18. Prostate diseases--role of sex steroids and their inhibitors.
Welén K; Damber JE
Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
[TBL] [Abstract][Full Text] [Related]
19. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
20. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
Krieg M; Bartsch W; Thomsen M; Voigt KD
J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
